Welcome to our dedicated page for ARTELO BIOSCIENCES SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artelo Biosciences, Inc. filings document a clinical-stage pharmaceutical issuer with securities listed on Nasdaq and a pipeline centered on lipid-signaling modulation. Registration statements and amendments describe securities offerings, delayed or continuous offering registration mechanics, common stock, warrants, pre-funded warrants and capital-structure terms.
Artelo's Form 8-K filings record material events including Nasdaq continued-listing compliance, annual-meeting matters, private-placement activity, material agreements, and clinical or regulatory disclosures for programs such as ART27.13 and ART26.12. The filings connect formal governance and financing records with updates on the company's drug-development strategy and intellectual-property activity.
Artelo Biosciences, Inc. (ARTL) approved a 1-for-9 reverse stock split of its common stock. The common stock is expected to begin trading on a split-adjusted basis on August 31, 2026 on the Nasdaq Capital Market.
Every nine shares of issued and outstanding common stock will be automatically combined into one share, with no fractional shares issued; holders otherwise entitled to a fraction will receive one whole share. The company states that each shareholder’s pro-rata ownership will remain unchanged, and all outstanding warrants and other derivatives will automatically adjust to reflect the reverse split. Immediately after effectiveness, there will be approximately 547,774 shares of common stock issued and outstanding.
Armistice Capital, LLC and Steven Boyd report that they no longer beneficially own any common stock of Artelo Biosciences, Inc. In this amended Schedule 13G, the reporting persons state beneficial ownership of 0 shares of Artelo common stock, representing 0.0% of the class as of June 30, 2026.
The filing confirms they have no sole or shared voting or dispositive power over Artelo shares. It also notes that Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., which has the right to receive dividends or sale proceeds on any reported securities under an Investment Management Agreement.
Artelo Biosciences, Inc. is reported as having a significant shareholder group consisting of Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC. As of the close of business on June 30, 2026, they may be deemed to have beneficial ownership of 173,914 shares of common stock, all issuable upon exercise of a warrant held by Intracoastal. This represents 4.8% of the common stock, based on 3,485,540 shares outstanding as of May 26, 2026 plus the warrant shares. The group reports no sole voting or dispositive power and shared voting and dispositive power over all 173,914 warrant shares, and indicates ownership of 5 percent or less of the class.
Artelo Biosciences, Inc. reported unaudited results for the quarter and six months ended June 30, 2026. The clinical-stage biopharmaceutical company remains pre-revenue and recorded a net loss of $2.4 million for the quarter and $5.4 million for the first half of 2026, broadly similar to the prior-year period. Operating expenses for the six months were $5.2 million, with $3.5 million in general and administrative costs and $1.6 million in research and development, reflecting reduced CAReS trial spending versus 2025.
Liquidity improved following equity financings and debt settlements. Cash and cash equivalents increased to $4.2 million at June 30, 2026 from $0.6 million at year-end 2025, and total liabilities fell to $1.5 million from $4.1 million, shifting stockholders’ equity from a deficit of $(1.3) million to positive $5.0 million. In March 2026 Artelo raised gross proceeds of $10.997 million (net $10.033 million) via a common stock and warrant private placement and fully settled its March 2026 convertible notes, recording a small gain on extinguishment of debt.
The company established a $75.0 million Form S-3 shelf and a $6.53 million at-the-market program, issuing 142,860 ATM shares for $0.174 million by June 30, 2026. Despite these actions, management disclosed that current resources are insufficient to fund operations for 12 months without additional capital, and expressed substantial doubt about Artelo’s ability to continue as a going concern.
Artelo Biosciences granted director Connie Matsui a stock option covering 136 shares of common stock at an exercise price of $1.15 per share, expiring on July 17, 2036. The option vests 100% on the earlier of the one-year anniversary of the July 17, 2026 Vesting Commencement Date or the day prior to the next annual stockholders’ meeting following that date, contingent on her continued service as a Service Provider.
ARTELO BIOSCIENCES granted director Douglas Blayney a stock option for 136 shares of common stock at an exercise price of $1.15 per share, expiring on July 17, 2036. The option vests 100% on the earlier of one year after the Vesting Commencement Date of July 17, 2026, or the day prior to the next annual stockholders’ meeting, subject to continued service.
Artelo Biosciences director Gregory Reyes received a grant of stock options covering 136 shares of common stock at an exercise price of $1.15 per share, expiring July 17, 2036. All options vest 100% on the earlier of one year after the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholder meeting, subject to his continued service.
Artelo Biosciences director Robert Martin received a grant of 136 stock options to purchase common stock at an exercise price of $1.15 per share. These options expire on July 17, 2036 and will vest 100% on the earlier of the one-year anniversary of the July 17, 2026 Vesting Commencement Date or the day prior to the next annual stockholders’ meeting after that date, subject to his continued service as a Service Provider under the issuer’s plan. Following this award, he holds 136 options from this grant, and the transaction is flagged as made pursuant to a Rule 10b5-1 trading arrangement.
ARTELO BIOSCIENCES, INC. reported that director Steven Kelly received a grant of stock options for 136 shares of common stock at an exercise price of $1.15 per share. The options vest 100% on the earlier of the one-year anniversary of a July 17, 2026 vesting commencement date or the day prior to the next annual stockholder meeting following that date, subject to continued service as a Service Provider, and expire on 2036-07-17.